ORKA (Oruka Therapeutics) Other Long-Term Liabilities : $0.00 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Oruka Therapeutics Other Long-Term Liabilities?

Oruka Therapeutics's other long-term liabilities for the quarter that ended in Dec. 2024 was $0.00 Mil.

Oruka Therapeutics's quarterly other long-term liabilities stayed the same from . 20 ($0.00 Mil) to . 20 ($0.00 Mil) but then increased from . 20 ($0.00 Mil) to Dec. 2024 ($0.00 Mil).

Oruka Therapeutics's annual other long-term liabilities stayed the same from . 20 ($0.00 Mil) to . 20 ($0.00 Mil) but then increased from . 20 ($0.00 Mil) to Dec. 2024 ($0.00 Mil).

Oruka Therapeutics Other Long-Term Liabilities Historical Data

The historical data trend for Oruka Therapeutics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oruka Therapeutics Other Long-Term Liabilities Chart

Oruka Therapeutics Annual Data

Trend

Dec24

Other Long-Term Liabilities

Oruka Therapeutics Semi-Annual Data
	Dec24
Other Long-Term Liabilities	-

Oruka Therapeutics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Oruka Therapeutics Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Oruka Therapeutics's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Oruka Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (NAS:ORKA) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025

Website

https://www.orukatx.com

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.